Combination therapy with HDAC and DNMT inhibitors alters the T cell exhaustion state to memory and effector T cell phenotypes [77], suggesting a possible therapeutic option against CTCL. This evidence concerns the gene DNMT1 and primary cutaneous T-cell non-Hodgkin lymphoma.